ATE320809T1 - Polymorphe, amorphe und hydratisierte formen von 5-chlor-3-(methansulfonylphenyl)-6'-methyl-2, 3')bipyridinyl - Google Patents

Polymorphe, amorphe und hydratisierte formen von 5-chlor-3-(methansulfonylphenyl)-6'-methyl-2, 3')bipyridinyl

Info

Publication number
ATE320809T1
ATE320809T1 AT00980817T AT00980817T ATE320809T1 AT E320809 T1 ATE320809 T1 AT E320809T1 AT 00980817 T AT00980817 T AT 00980817T AT 00980817 T AT00980817 T AT 00980817T AT E320809 T1 ATE320809 T1 AT E320809T1
Authority
AT
Austria
Prior art keywords
amorphous
methansulfonylphenyl
polymorphous
bipyridinyl
chlorine
Prior art date
Application number
AT00980817T
Other languages
English (en)
Inventor
Sophie Dorothee Clas
Paul O'shea
Chad Dalton
Louis S Crocker
James A Mccauley
Richard D Tillyer
Ian Davies
Original Assignee
Merck Frosst Canada Inc
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada Inc, Merck & Co Inc filed Critical Merck Frosst Canada Inc
Application granted granted Critical
Publication of ATE320809T1 publication Critical patent/ATE320809T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
AT00980817T 1999-11-29 2000-11-27 Polymorphe, amorphe und hydratisierte formen von 5-chlor-3-(methansulfonylphenyl)-6'-methyl-2, 3')bipyridinyl ATE320809T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16792299P 1999-11-29 1999-11-29

Publications (1)

Publication Number Publication Date
ATE320809T1 true ATE320809T1 (de) 2006-04-15

Family

ID=22609368

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00980817T ATE320809T1 (de) 1999-11-29 2000-11-27 Polymorphe, amorphe und hydratisierte formen von 5-chlor-3-(methansulfonylphenyl)-6'-methyl-2, 3')bipyridinyl

Country Status (11)

Country Link
US (3) US6441002B1 (de)
EP (1) EP1248618B1 (de)
JP (1) JP4425514B2 (de)
AT (1) ATE320809T1 (de)
AU (1) AU776544B2 (de)
CA (1) CA2391650C (de)
DE (1) DE60026877T2 (de)
DK (1) DK1248618T3 (de)
ES (1) ES2259295T3 (de)
PT (1) PT1248618E (de)
WO (1) WO2001037833A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12001001175B1 (en) * 2000-05-26 2006-08-10 Merck Sharp & Dohme 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- (2,3')bipyridinyl in pure crystalline form and process for synthesis
US6521642B2 (en) 2000-05-26 2003-02-18 Merck & Co., Inc. 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl in pure crystalline form and process for synthesis
WO2005085199A1 (en) * 2004-01-14 2005-09-15 Cadila Healthcare Limited Novel polymorphs of etoricoxib
PL2401253T3 (pl) 2009-02-27 2016-05-31 Cadila Healthcare Ltd Sposób otrzymywania etorykoksybu
EA023286B1 (ru) * 2011-05-27 2016-05-31 ФАРМА ДжРС, Д.О.О. Способ получения полиморфной формы i эторикоксиба
WO2013105106A1 (en) 2011-11-03 2013-07-18 Cadila Healthcare Limited An improved process for the preparation of etoricoxib and polymorphs thereof
WO2013075732A1 (en) 2011-11-21 2013-05-30 Synthon Bv Process for making crystalline form i of etoricoxib
EP2601952A1 (de) 2011-12-07 2013-06-12 Zentiva, k.s. Neue pharmazeutisch annehmbare Salze und Kokristalle von 5-Chlor-3-(4-methansulfonylphenyl)-6'-methyl-[2,3']bipyridinyl und ihre therapeutische Anwendungen
WO2013144977A2 (en) * 2012-03-30 2013-10-03 Mylan Laboratories Ltd. An improved process for the preparation of etoricoxib
EP2888231B1 (de) 2012-08-27 2019-01-09 Glenmark Pharmaceuticals Limited Verfahren zur herstellung von kristallinem etoricoxib
CN104418799A (zh) * 2013-09-03 2015-03-18 天津药物研究院 一种依托考昔的晶型及其制备方法和应用
WO2015036550A1 (en) 2013-09-13 2015-03-19 Synthon B.V. Process for making etoricoxib
CN107056691B (zh) * 2017-06-21 2020-03-10 四川尚锐生物医药有限公司 一种制备依托考昔晶型v的方法
MX2018013070A (es) 2017-12-29 2019-10-15 Gruenenthal Gmbh Combinación farmacéutica que comprende clorhidrato de tramadol de liberación extendida y etoricoxib de liberación inmediata, y su uso para el tratamiento del dolor.
CN111410629A (zh) * 2020-03-31 2020-07-14 天津大学 依托考昔溶剂化物及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5321033A (en) 1991-11-15 1994-06-14 Merck Frosst Canada, Inc. Amorphous (quinolin-2-ylmethoxy)indole compounds useful for treating inflammatory diseases
US5861419A (en) * 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
SK283261B6 (sk) 1996-07-18 2003-04-01 Merck Frosst Canada & Co. / Merck Frosst Canada & Cie. Substituované pyridíny, farmaceutický prostriedok s ich obsahom a ich použitie
US6127545A (en) 1997-04-18 2000-10-03 Merck & Co., Inc. Process for making 2-aryl-3-aryl-5-halo pyridines useful as COX-2 inhibitors
US6130334A (en) 1998-04-15 2000-10-10 Merck & Co., Inc. Process for making 2-aryl-3-aryl-5-halo pyridines useful as COX-2 inhibitors
US6040450A (en) 1997-09-25 2000-03-21 Merck & Co., Inc. Process for making diaryl pyridines useful as cox-2-inhibitors
EA002975B1 (ru) 1998-04-24 2002-12-26 Мерк Энд Ко., Инк. Способ синтеза ингибиторов циклооксигеназы-2
US6521642B2 (en) * 2000-05-26 2003-02-18 Merck & Co., Inc. 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl in pure crystalline form and process for synthesis
PH12001001175B1 (en) * 2000-05-26 2006-08-10 Merck Sharp & Dohme 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- (2,3')bipyridinyl in pure crystalline form and process for synthesis

Also Published As

Publication number Publication date
EP1248618B1 (de) 2006-03-22
ES2259295T3 (es) 2006-10-01
US6441002B1 (en) 2002-08-27
EP1248618A4 (de) 2003-05-14
WO2001037833A1 (en) 2001-05-31
JP4425514B2 (ja) 2010-03-03
PT1248618E (pt) 2006-07-31
CA2391650A1 (en) 2001-05-31
DK1248618T3 (da) 2006-07-10
US20020198238A1 (en) 2002-12-26
US20030144327A1 (en) 2003-07-31
AU776544B2 (en) 2004-09-16
CA2391650C (en) 2011-01-25
EP1248618A1 (de) 2002-10-16
DE60026877T2 (de) 2006-11-23
AU1803101A (en) 2001-06-04
DE60026877D1 (de) 2006-05-11
JP2003514859A (ja) 2003-04-22

Similar Documents

Publication Publication Date Title
ATE320809T1 (de) Polymorphe, amorphe und hydratisierte formen von 5-chlor-3-(methansulfonylphenyl)-6'-methyl-2, 3')bipyridinyl
ID19602A (id) Piridin tersubstitusi sebagai inhibitor selektif siklooksigenase-2
ATE222256T1 (de) Polymorphe form von clopidogrel-hydrogenosulfat
PT1240104E (pt) Producao continua de microgeis de base em silica
FI982738A0 (fi) Lähettimen linearisointi
DE69905158D1 (de) Inkrementales aktualisieren
ATE250408T1 (de) Clindamycin enthaltendes intravaginalzäpfchen
AU5996201A (en) Microphysiometer
DE69630842D1 (de) Steinbohrer
DE69709938D1 (de) N-benzylpiperidin- und tetrahydropyridin-derivate
IS6338A (is) 4-karboxýamínó-2-etýl-1,2,3,4-tetrahýdrókínólín kristall sem CETP lati
NO20010298D0 (no) Polymorf av et formakum
AR028607A1 (es) Derivados de 1,4-diazepan-2,5-diona
NO20005285L (no) Styring av multiple nedihullsverktöy
NO20020717L (no) Produksjon av dampavsatt silika
ID22326A (id) Struktur montasi sarung garpu
DE59913178D1 (de) Bohrgestängeverbinder
EE05234B1 (et) 6-karboksamidoimidaso[1,2-a] pridiinihendite kasutamine ravimi p?hjustatud maohaavandi v„ltimiseks
NO20011056L (no) Fremgangsmate for utvelging av stivelse
ID30349A (id) Turunan benzo (5,6) siklohepta (1,2-b) piridin untuk menghambat transferase protein farnesil
KR970002359U (ko) 가스캔 구멍뚫이개
FI982739A0 (fi) Lähettimen linearisointi
SI1248618T1 (sl) Polimorfne, amorfne in hidratirane oblike 5-kloro-3-(4-metansulfonilfenil)-6'-metil-2,3')bipiridinila
ES1045877Y (es) Disposicion de fieltros autoadhesivos.
NO985604D0 (no) FremgangsmÕte til kopolymerisasjon av tiofener

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1248618

Country of ref document: EP

EEFA Change of the company name